Dyne Therapeutics (DYN) Projected to Announce Earnings on Wednesday

Dyne Therapeutics (NASDAQ:DYN) will likely be releasing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Dyne Therapeutics to post earnings of ($0.9073) per share for the quarter. Investors can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 3:00 PM ET.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Wednesday, July 29th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). On average, analysts expect Dyne Therapeutics to post ($3.59) EPS for the current fiscal year and ($3.28) EPS for the next fiscal year.

Dyne Therapeutics Price Performance

DYN stock opened at $16.69 on Monday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 12.02 and a current ratio of 12.02. Dyne Therapeutics has a 52 week low of $14.00 and a 52 week high of $27.31. The firm’s fifty day moving average is $18.53 and its 200 day moving average is $19.31. The firm has a market cap of $3.12 billion, a P/E ratio of -5.01 and a beta of 1.22.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on DYN. Oppenheimer lowered shares of Dyne Therapeutics from an “outperform” rating to a “market perform” rating and cut their price target for the company from $40.00 to $15.00 in a research report on Wednesday, October 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Thursday, October 15th. Wall Street Zen cut Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Raymond James Financial restated a “strong-buy” rating and set a $37.00 target price on shares of Dyne Therapeutics in a report on Tuesday, September 8th. Finally, Cantor Fitzgerald restated a “buy” rating on shares of Dyne Therapeutics in a research report on Wednesday, September 30th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $31.29.

Insider Activity

In other Dyne Therapeutics news, CEO John Cox sold 5,658 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total value of $106,823.04. Following the transaction, the chief executive officer owned 357,507 shares in the company, valued at approximately $6,749,732.16. The trade was a 1.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jason P. Rhodes sold 2,160,516 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the transaction, the director directly owned 428,946 shares of the company’s stock, valued at approximately $10,723,650. This trade represents a 83.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 2,598,706 shares of company stock worth $65,432,671. 9.46% of the stock is currently owned by corporate insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for serious muscle diseases. The company’s research is centered on conditions in which the delivery of therapeutic molecules to skeletal muscle and other tissues is a significant challenge.

Dyne uses its proprietary FORCE platform to design targeted therapies intended to improve the delivery of oligonucleotides into muscle cells. The platform incorporates antibodies that bind to the transferrin receptor, which can help transport genetic medicines across cell membranes and into muscle tissue.

Dyne’s pipeline includes DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.